CHRS
Coherus Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.42
+3.65%Year over year
Reported trailing growth
- Revenue
- -64.3%
- EBITDA
- -10.8%
- EBIT
- -12.2%
- EPS
- +27.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +52.9%
- EBITDA
- +18.4%
- EPS
- +15.7%
Three-year CAGR
- Revenue
- -41.5%
- EBITDA
- —
- EBIT
- -60.8%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026